392 related articles for article (PubMed ID: 31984569)
1. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
[TBL] [Abstract][Full Text] [Related]
2. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
3. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J
Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899
[TBL] [Abstract][Full Text] [Related]
4. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
7. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
8. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
9. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
11. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Okuji T; Ito M; Onoue T; Goto M; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Fujimoto Y; Hibi H; Sone M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32606047
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
13. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
14. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
16. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
19. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
Nomura M; Oze I; Masuishi T; Yokota T; Satake H; Iwasawa S; Kato K; Andoh M
Int J Clin Oncol; 2020 May; 25(5):972-977. PubMed ID: 31938955
[TBL] [Abstract][Full Text] [Related]
20. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab.
Kono Y; Choda Y; Nakagawa M; Miyahara K; Ishida M; Kubota T; Seo K; Hirata T; Obayashi Y; Gotoda T; Moritou Y; Okikawa Y; Iwamoto Y; Okada H
Target Oncol; 2021 Mar; 16(2):237-248. PubMed ID: 33475927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]